| Name | belizatinib |
|---|---|
| Synonyms |
Benzamide, 4-fluoro-N-[6-[[4-(1-hydroxy-1-methylethyl)-1-piperidinyl]methyl]-1-[cis-4-[[(1-methylethyl)amino]carbonyl]cyclohexyl]-1H-benzimidazol-2-yl]
TSR-011 4-Fluoro-N-(6-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-1-(cis-4-(isopropylcbamoyl)cyclohexyl)-1H-benzo[d]imidazol-2-yl)benzamide TSR011; TSR011; TSR 011; BELIZATINIB 4-Fluoro-N-(6-{[4-(2-hydroxy-2-propanyl)-1-piperidinyl]methyl}-1-[cis-4-(isopropylcarbamoyl)cyclohexyl]-1H-benzimidazol-2-yl)benzamide Belizatinib (TSR011) TSR011,Trk Rector,CD246,ALK tyrosine kinase rector,Tropomyosin related kinase rector,TSR 011,inhibit,Cluster of differentiation 246,Belizatinib,Inhibitor,Anaplastic lymphoma kinase,Anaplastic lymphoma kinase (ALK) Belizatinib, 10 mM in DMSO |
| Description | Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7 nM for wild-type recombinant ALK kinase. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.7 nM (ALK)[1] |
| In Vitro | TSR-011 has antitumour activity in the clinical trials. |
| In Vivo | TSR-011 exerts sustained potent inhibition of ALK-dependent tumour growth in mouse models[1]. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Molecular Formula | C33H44FN5O3 |
| Molecular Weight | 577.733 |
| Exact Mass | 577.342834 |
| LogP | 3.99 |
| Index of Refraction | 1.631 |
| Storage condition | -20℃ |
| Hazard Codes | N |
|---|